Corcept Therapeutics Commences Late-Stage Ovarian Cancer Study


Corcept Therapeutics CORT has initiated pivotal Phase 3 clinical trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer.

ROSELLA study is a pivotal Phase 3 clinical trial designed to evaluate relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer. The study has a target of enrolling 360 women subjects with recurrent, platinum-resistant ovarian cancer.

The primary endpoint of this study will be progression-free survival, with overall survival as a key secondary endpoint.

Bill Guyer, Chief Development Officer, said, "We are excited that our ROSELLA study is now open. Our Phase 2 study demonstrated improvements in progression free survival, duration of response and overall survival without increased side effect burden. Our goal in Phase 3 is to replicate these positive results, which would be of unprecedented benefit to women with platinum-resistant ovarian cancer, for whom relacorilant plus nab-paclitaxel has the potential to become a new standard of care."

Ovarian cancer is the most common cause of cancer death in women. Patients whose disease returns less than six months after receiving platinum-containing therapy are described as having platinum-resistant disease.

Corcept shares closed Wednesday’s trading up 2 percent at $24.74

Market News and Data brought to you by Benzinga APIs
Posted In: BiotechHealth CareGeneralClinical Study Initiation
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!